| ID | 118977 |
| 著者 |
Yamashita, H
Kanaiso Hospital
板東, 浩
Kanaiso Hospital|Tokushima University|Medical Research|Japan Low Carbohydrate Diet Promotion Association
KAKEN研究者をさがす
Kato, Y
Kanaiso Hospital
Ogura, K
Kanaiso Hospital
Kato, Y
Kanaiso Hospital
Kawata, T
Kanaiso Hospital
|
| キーワード | Oral semaglutide (Rybelsus)
Gastrointestinal adverse events (GIAEs)
Semaglutide Treatment Effect in People with Obesity (STEP)
Glucagon-Like Peptide 1 receptor agonist (GLP-1RA)
Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Background: Recent topic for diabetes includes oral semaglutide (Rybelsus).
Case presentation: A Patient is 75-year-old female with Type 2 diabetes (T2D). Her HbA1c has been 6.8-7.6% for long, but increased to 8.4-8.8% in Jan 2022 with BMI 27.6 kg/m2. Results: She started Rybelsus 3-7mg/day, and then weight and HbA1c decreased as 7kg and 1.6% in 4 months. Discussion: Rybelsus is known for improvement of weight and glucose variability. For her clinical effects, some probable reasons include ‘70s for age, less developed microangiopathy and macroangiopathy, longer fasting time period after Rybelsus intake. This case will become useful reference for diabetic research. |
| 掲載誌名 |
SunText Review of Case Reports & Images
|
| ISSN | 27664589
|
| 出版者 | SunText Reviews
|
| 巻 | 3
|
| 号 | 2
|
| 開始ページ | 147
|
| 発行日 | 2022-06-27
|
| 権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
